Sign In
Buy GBIO
$5.34
+0 (+0%)
At Close: May 05, 2026
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
06:15pm, Monday, 13'th May 2024
Generation Bio Co. (GBIO) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.53 per share a year ago.
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
04:05pm, Monday, 13'th May 2024
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP)
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
06:59am, Thursday, 09'th May 2024
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today pr
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today ann
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
06:59am, Tuesday, 02'nd Apr 2024
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
06:41pm, Wednesday, 06'th Mar 2024
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.55 per share a year ago.
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
04:20pm, Wednesday, 06'th Mar 2024
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
06:59am, Tuesday, 27'th Feb 2024
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 03'rd Jan 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
3 Penny Stocks To Buy According To Insiders In December
03:36pm, Thursday, 07'th Dec 2023
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
06:59am, Wednesday, 29'th Nov 2023
CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
04:15pm, Thursday, 09'th Nov 2023
- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
06:59am, Thursday, 26'th Oct 2023
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
08:15am, Friday, 20'th Oct 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
06:59am, Wednesday, 18'th Oct 2023
– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tol
